{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:30:44Z","timestamp":1768455044563,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Ratchadapisek Sompoch Endowment Fund of Chulalongkorn University"},{"name":"Second Century Fund"},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A one-month regimen of daily isoniazid plus rifapentine (1HP) is endorsed by WHO for latent tuberculosis infection (LTBI), showing efficacy and safety in people with human immunodeficiency virus (HIV). However, the pharmacokinetics (PK) of rifapentine in end-stage renal disease (ESRD) patients on dialysis remain unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a 24-hour multiple-dose PK study of daily rifapentine in 11 dialysis-dependent patients with LTBI. Participants received rifapentine 450\u2013600\u2005mg plus isoniazid 300\u2005mg daily for 4 weeks. Plasma samples were collected on day 14 at eight time points: pre-dose and 1, 2, 4, 6, 8, 12 and 24\u2005hours post-dose. Rifapentine concentrations were measured using validated HPLC. PK parameters were compared with historical cohort from non-dialysed populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants (63% male, mean age 49) received a mean rifapentine dose of 9.9\u202f\u00b1\u202f1.6\u202fmg\/kg. Eleven (69%) completed treatment; five discontinued due to adverse events or transplantation. Median maximum concentration (Cmax) was 11.4\u2005\u00b5g\/mL (IQR, 8.7\u201313.7); median AUC0\u201324 was 177\u2005\u00b5g\u00b7h\/mL (IQR, 134\u2013206).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rifapentine exposure in dialysis patients was lower than in non-dialysed historical cohorts, highlighting the need for larger studies to refine dosing in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf439","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:46:14Z","timestamp":1763469974000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients"],"prefix":"10.1093","volume":"81","author":[{"given":"Thornthun","family":"Ueaphongsukkit","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4087-9032","authenticated-orcid":false,"given":"Suwasin","family":"Udomkarnjananun","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Department of Medicine, Center of Excellence in Renal Immunology and Renal Transplantation, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Excellence Center for Organ Transplantation, King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakapat","family":"Vanichanan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamonwan","family":"Jutivorakool","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natavudh","family":"Townamchai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Department of Medicine, Center of Excellence in Renal Immunology and Renal Transplantation, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Excellence Center for Organ Transplantation, King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salin","family":"Wattanatorn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phalin","family":"Kamolwat","sequence":"additional","affiliation":[{"name":"Department of Disease Control, Tuberculosis Division, Ministry of Public Health , Nonthaburi ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasiwimol","family":"Ubolyam","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS Research Centre , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J","family":"Kerr","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS Research Centre , Bangkok ,","place":["Thailand"]},{"name":"Biostatistics Excellence Centre, Research Affairs, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"The Kirby Institute, University of New South Wales , Sydney ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS Research Centre , Bangkok ,","place":["Thailand"]},{"name":"Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-6020","authenticated-orcid":false,"given":"Pajaree","family":"Chariyavilaskul","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyos","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Department of Medicine, Center of Excellence in Renal Immunology and Renal Transplantation, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Excellence Center for Organ Transplantation, King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"2026011413281206800_dkaf439-B1","volume-title":"Global Tuberculosis Report 2024","author":"World Health Organization","year":"2024"},{"key":"2026011413281206800_dkaf439-B2","doi-asserted-by":"publisher","first-page":"e13566","DOI":"10.1111\/tid.13566","article-title":"Risk factors and clinical outcomes of tuberculosis among kidney transplant recipients in high endemic country","volume":"23","author":"Thitisuriyarax","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"2026011413281206800_dkaf439-B3","volume-title":"Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management","author":"World Health Organization","year":"2018"},{"key":"2026011413281206800_dkaf439-B4","doi-asserted-by":"publisher","first-page":"e3459","DOI":"10.1093\/cid\/ciaa1364","article-title":"Higher completion rates with self-administered once-weekly isoniazid-rifapentine versus daily rifampin in adults with latent tuberculosis","volume":"73","author":"Haas","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026011413281206800_dkaf439-B5","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011413281206800_dkaf439-B6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2026011413281206800_dkaf439-B7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijid.2022.07.040","article-title":"Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection","volume":"122","author":"Phaisal","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026011413281206800_dkaf439-B8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1164\/rccm.201912-2489OC","article-title":"Rifapentine population pharmacokinetics and dosing recommendations for latent tuberculosis infection","volume":"202","author":"Hibma","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026011413281206800_dkaf439-B9","doi-asserted-by":"publisher","first-page":"A6341","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A6341","article-title":"Rifapentine exposure in a trial of daily rifapentine compared to rifampin during the intensive phase of TB treatment","volume":"183","author":"Weiner","year":"2011","journal-title":"Am J Resp Crit Care"},{"key":"2026011413281206800_dkaf439-B10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin Pharmacol Therap"},{"key":"2026011413281206800_dkaf439-B11","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1128\/AAC.00345-10","article-title":"Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers","volume":"54","author":"Zvada","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413281206800_dkaf439-B12","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.2215\/CJN.05150418","article-title":"Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens","volume":"13","author":"Roberts","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026011413281206800_dkaf439-B13"},{"key":"2026011413281206800_dkaf439-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2015.10.018","article-title":"Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment","volume":"42","author":"Strunk","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2026011413281206800_dkaf439-B15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/jac\/46.4.565","article-title":"Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG","volume":"46","author":"Rastogi","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2026011413281206800_dkaf439-B16","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413281206800_dkaf439-B17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jmii.2018.05.003","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: high rates of adverse events","volume":"52","author":"Lin","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"2026011413281206800_dkaf439-B18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.jfma.2020.10.008","article-title":"An observational study on prevalence of latent tuberculosis infection and outcome of 3HP treatment in patients under hemodialysis in Taiwan","volume":"120","author":"Wu","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"2026011413281206800_dkaf439-B19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000187331","article-title":"Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature","volume":"64","author":"Siskind","year":"1993","journal-title":"Nephron"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf439\/65923897\/dkaf439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf439\/65923897\/dkaf439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:28:17Z","timestamp":1768415297000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf439\/8381494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf439","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,16]]},"article-number":"dkaf439"}}